The -670A > G polymorphism in the promoter region of the FAS gene is associated with necrosis in periportal areas in patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 12, Issue 6, 2005, Pages 568-573

  Aguilar Reina, José ^a   Ruiz Ferrer, M ^a   Pizarro, Ma A ^a   Antinolo G ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Apoptosis; Genetics; Hepatitis C virus infection; Susceptibility factor

Indexed keywords

DEATH RECEPTOR; FAS ANTIGEN;

ADULT; APOPTOSIS; ARTICLE; CHRONIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEPATITIS C; HUMAN; HUMAN TISSUE; INFECTION RISK; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; LIVER NECROSIS; MALE; MOLECULAR PROBE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SCORING SYSTEM; UPREGULATION;

ADOLESCENT; ADULT; ANTIGENS, CD95; APOPTOSIS; BASE SEQUENCE; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NECROSIS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 27444440027     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00639.x     Document Type: Article

References (34)

1. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832.
2. Hayashi N, Mita E. Fas system and apoptosis in viral hepatitis. J Gastroenterol Hepatol 1997; 12: 223-226.
3. Lau JY, Xie X, Lai MM, Wu PC. Apoptosis and viral hepatitis. Semin Liver Dis 1998; 18: 169-176.
4. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
5. Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature 1996; 384: 638-641.
6. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-512.
7. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995; 270: 7795-7798.
8. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996; 85: 803-815.
9. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci 1997; 22: 299-306.
10. Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. An induced proximity model for caspase-8 activation. J Biol Chem 1998; 273: 2926-2930.
11. Watanabe-Fukunaga R, Brannan CI, Itoh N et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992; 148: 1274-1279.
12. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
13. Hiramatsu N, Hayashi N, Katayama K et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19: 1354-1359.
14. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997; 34: 577-582.
15. Kavurma MM, Santiago FS, Bonfoco E, Khachigian LM. Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement. J Biol Chem 2001; 276: 4964-4971.
16. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
17. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
18. Dracapoly NH, Seidman CE, Seidman JG, Smith DR. Current Protocols in HUMAN Genetics, Vol. 1. New York: John Wilet & Sons, 1996.
19. Huang QR, Manolios N. Investigation of the -1377 polymorphism on the Apo-1/Fas promoter in systemic lupus erythematosus patients using allele-specific amplification. Pathology 2000; 32: 126-130.
20. Huang QR, Danis V, Lassere M, Edmonds J, Manolios N. Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology 1999; 38: 645-651.
21. Kerr JF, Cooksley WG, Searle J et al. The nature of piecemeal necrosis in chronic active hepatitis. Lancet 1979; 2: 827-828.
22. Ruggieri A, Harada T, Matsuura Y, Miyamura T. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology 1997; 229: 68-76.
23. Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J Virol 1999; 73: 4713-4720.
24. Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol 1995; 69: 3893-3896.
25. Gale M Jr, Kwieciszewski B, Dossett M, Nakao H, Katze MG. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol 1999; 73: 6506-6516.
26. Miyasaka Y, Enomoto N, Kurosaki M et al. Hepatitis C virus nonstructural protein 5A inhibits tumor necrosis factor-alpha-mediated apoptosis in Huh7 cells. J Infect Dis 2003; 188: 153715-153744.
27. Calabrese F, Pontisso P, Pettenazzo E et al. Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology 2000; 31: 1153-1159.
28. Kanemitsu S, Ihara K, Saifddin A et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 2002; 29: 1183-1188.
29. Feuk L, Prince JA, Blennow K, Brookes AJ. Further evidence for role of a promoter variant in the TNFRSF 6 gene in Alzheimer disease. Hum Mutat 2003; 21: 53-60.
30. van Veen T, Kalkers NF, Crusius JB et al. The FAS-670 polymorphism influences susceptibility to multiple sclerosis. J Neuroimmunol 2002; 128: 95-100.
31. Sibley K, Rollinson S, Allan JM et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003; 63: 4327-4330.
32. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996; 24: 759-765.
33. Pearse RN, Feinman R, Shuai K, Darnell JE Jr, Ravetch JV. Interferon gamma-induced transcription of the high-affinity Fc receptor for IgG requires assembly of a complex that includes the 91-kDa subunit of transcription factor ISGF3. Proc Natl Acad Sci USA 1993; 90: 4314-4318.
34. Gao J, Morrison DC, Parmely TJ, Russell SW, Murphy WJ. An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide. J Biol Chem 1997; 272: 1226-1230.